Arcellx (ACLX) Capital Leases (2022 - 2023)
Arcellx (ACLX) recorded quarterly Capital Leases of $5.8 million in Q3 2023, down 34.91% quarter-over-quarter from $8.8 million in Q2 2023, and down 78.73% on a YoY basis from $27.1 million in Q3 2022.
Arcellx (ACLX) Capital Leases (2022 - 2023) Analysis & Trends
Arcellx's Capital Leases history runs 2 years deep, the most recent figure standing at $5.8 million for Q3 2023.
- In Q3 2023, Capital Leases fell 78.73% year-over-year to $5.8 million; the TTM figure through Sep 2023 stood at $5.8 million (down 78.73% YoY), while the FY2022 annual figure was $20.9 million, changed N/A from the prior year.
- Capital Leases was $5.8 million for Q3 2023 at Arcellx, down from $8.8 million in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $27.1 million in Q3 2022 to a low of $5.8 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 5.76 Mn |
| Jun 30, 2023 | 8.84 Mn |
| Mar 31, 2023 | 15.41 Mn |
| Dec 31, 2022 | 20.87 Mn |
| Sep 30, 2022 | 27.05 Mn |